Yes, many peptides are real, FDA-approved peptide medicines. They include semaglutide, tirzepatide, oxytocin, octreotide and leuprolide. Table 1 lists the 70 approved medicines that have a complete guide in our library, with each brand, first approval year and labeled use. Sources were checked on November 17, 2026.
Quick answer: FDA has approved dozens of peptide medicines, from insulin analogs and GLP-1 drugs to older hormones such as oxytocin and vasopressin. Nearly all are prescription medicines, and each has an official label. The newest in our list are enlicitide (Lipfendra) and rusfertide (Mimrylo), both approved in 2026. Being "a peptide" says nothing about whether a product is approved.
Which peptides are FDA-approved?
Table 1 is built from our library's complete guides for FDA-approved compounds. We checked each first approval year against Drugs@FDA or the label's initial U.S. approval date. Each name links to the guide, which links the official label. The table is not every peptide drug FDA has approved; liraglutide, for example, has no guide yet.
FDA-approved peptide medicines in our library (checked November 17, 2026)
| Medicine | US brand | First approved | Labeled use, in short |
|---|---|---|---|
| Abaloparatide | Tymlos | 2017 | Osteoporosis in certain adults |
| Afamelanotide | Scenesse | 2019 | Light-triggered pain in EPP |
| Angiotensin II | Giapreza | 2017 | Low blood pressure in shock |
| Bacitracin | Generic ointments | By 1971 | Minor wounds, some eye infections (injectable withdrawn) |
| Bivalirudin | Angiomax | 2000 | Anticoagulant during PCI |
| Bremelanotide (PT-141) | Vyleesi | 2019 | Low sexual desire (HSDD) in premenopausal women |
| Calcitonin salmon | Miacalcin | 1975 | Paget's disease, osteoporosis, high calcium |
| Cetrorelix | Cetrotide | 2000 | Assisted reproduction |
| Corticotropin | Acthar Gel | 1950 | Infantile spasms, MS flares, other conditions |
| Cosyntropin | Cortrosyn | 1970 | Adrenal function test |
| Cyclosporine | Sandimmune, Neoral, Restasis | 1983 | Transplant rejection; dry eye |
| Dalbavancin, oritavancin, telavancin | Dalvance, Orbactiv, Vibativ | 2009 | Skin infections; pneumonia (Vibativ) |
| Daptomycin | Cubicin (discontinued); generics | 2003 | Skin and bloodstream infections |
| Dasiglucagon | Zegalogue (discontinued) | 2021 | Severe low blood sugar |
| Degarelix | Firmagon | 2008 | Advanced prostate cancer |
| Desirudin | Iprivask (discontinued) | 2003 | Clot prevention after hip replacement |
| Desmopressin | DDAVP | 1978 | Diabetes insipidus, bedwetting, bleeding disorders |
| Difelikefalin | Korsuva | 2021 | Itch in dialysis patients |
| Ecallantide | Kalbitor | 2009 | Hereditary angioedema attacks |
| Echinocandins | Eraxis, Rezzayo, generics | 2001 | Candida and some mold infections |
| Elamipretide (SS-31) | Forzinity | 2025 | Muscle strength in Barth syndrome (accelerated) |
| Enfuvirtide | Fuzeon (discontinued) | 2003 | HIV-1 in treated patients |
| Enlicitide | Lipfendra | 2026 | High LDL cholesterol |
| Eptifibatide | Integrilin (discontinued); generics | 1998 | Acute coronary syndrome, PCI |
| Etelcalcetide | Parsabiv | 2017 | Hyperparathyroidism on dialysis |
| Gallium Ga 68 dotatate | Netspot | 2016 | PET scan of neuroendocrine tumors |
| Ganirelix | Generic; Fyremadel | 1999 | Assisted reproduction |
| Glucagon | Baqsimi, Gvoke, generics | 1960 | Severe low blood sugar |
| Goserelin | Zoladex | 1989 | Prostate and breast cancer, endometriosis |
| hCG | Pregnyl, Ovidrel, unbranded | By 1973 | Fertility, hypogonadism (not weight loss) |
| Histrelin | Supprelin LA; Vantas (discontinued) | 1991 | Early puberty |
| Icatibant | Firazyr | 2011 | Hereditary angioedema attacks |
| Insulin analogs | Humalog and others | 1996 | Blood sugar control in diabetes |
| Lanreotide | Somatuline Depot | 2007 | Acromegaly, neuroendocrine tumors |
| Leuprolide | Lupron Depot, Eligard | 1985 | Prostate cancer, endometriosis, early puberty |
| Linaclotide | Linzess | 2012 | IBS-C, chronic constipation |
| Lutetium Lu 177 dotatate | Lutathera | 2018 | Neuroendocrine tumors |
| Lutetium Lu 177 vipivotide tetraxetan | Pluvicto | 2022 | PSMA-positive prostate cancer |
| Mecasermin | Increlex | 2005 | Severe IGF-1 deficiency in children |
| Motixafortide | Aphexda | 2023 | Stem cell collection in myeloma |
| Nafarelin | Synarel | 1990 | Early puberty, endometriosis |
| Nesiritide | Natrecor (discontinued) | 2001 | Acute heart failure |
| Octreotide | Sandostatin, Mycapssa | 1988 | Acromegaly, carcinoid and VIPoma symptoms |
| Oxytocin | Pitocin | 1980 | Labor and after delivery |
| Palopegteriparatide | Yorvipath | 2024 | Hypoparathyroidism in adults |
| Parathyroid hormone | Natpara (no longer supplied) | 2015 | Hypoparathyroidism |
| Pasireotide | Signifor | 2012 | Cushing's disease, acromegaly |
| Pegcetacoplan | Empaveli, Syfovre | 2021 | PNH, kidney disease, geographic atrophy |
| Pegvisomant | Somavert | 2003 | Acromegaly |
| Plecanatide | Trulance | 2017 | Chronic constipation, IBS-C |
| Polymyxin B and colistin | Generics | By 1964 | Serious gram-negative infections |
| Rusfertide | Mimrylo | 2026 | Polycythemia vera |
| Secretin | ChiRhoStim | 2004 | Pancreas and gastrinoma tests |
| Semaglutide | Ozempic, Rybelsus, Wegovy | 2017 | Type 2 diabetes, weight, heart risk, MASH |
| Setmelanotide | Imcivree | 2020 | Certain rare genetic or hypothalamic obesity |
| Sincalide | Kinevac | 1976 | Gallbladder and pancreas tests |
| Somapacitan | Sogroya | 2020 | Growth hormone deficiency |
| Somatropin | Genotropin, Humatrope, others | 1987 | Growth failure; adult GH deficiency |
| Teduglutide | Gattex | 2012 | Short bowel syndrome |
| Terlipressin | Terlivaz | 2022 | Hepatorenal syndrome |
| Teriparatide | Forteo (2002), Bonsity | 1987 | Osteoporosis in certain adults |
| Tesamorelin | Egrifta SV, Egrifta WR | 2010 | Belly fat in HIV lipodystrophy (not weight loss) |
| Tirzepatide | Mounjaro, Zepbound | 2022 | Type 2 diabetes, weight, sleep apnea |
| Triptorelin | Trelstar, Triptodur | 2000 | Prostate cancer, early puberty |
| Trofinetide | Daybue | 2023 | Rett syndrome |
| Vancomycin | Vancocin, generics | 1958 | Gram-positive infections, C. difficile |
| Vasopressin | Vasostrict | 2014 | Low blood pressure in shock |
| Vosoritide | Voxzogo | 2021 | Growth in achondroplasia (accelerated) |
| Ziconotide | Prialt | 2004 | Severe chronic pain |
| Zilucoplan | Zilbrysq | 2023 | Generalized myasthenia gravis |
Notes on Table 1. "By" means the earliest dated record we found in Drugs@FDA; older records carry no date. Calcitonin salmon, somatropin, teriparatide and vancomycin use the initial U.S. approval year printed on current labels. "Accelerated" marks an indication approved under accelerated approval. Brands marked discontinued are listed that way in Drugs@FDA.
What counts as a peptide medicine?
A peptide is a short chain of amino acids. FDA draws a line in its rules. A protein is any amino acid chain of defined sequence "greater than 40 amino acids in size" (21 CFR 600.3). Chains of 40 or fewer fall below that line.
Some medicines in Table 1 sit above that line, such as insulin analogs, somatropin and hCG. We include them because our library covers them alongside the peptide hormones. Since March 23, 2020, approved applications for certain biological products, hCG among them, have been treated as biologics licenses (FDA, 2020). For the chemistry, see what a polypeptide is and types of peptides.
What does FDA approval cover, and what does it not?
Approval belongs to a specific product, made by a specific company, for the uses on its label. It does not pass to anything else that shares the ingredient's name.
- Compounded drugs. FDA states that "compounded drugs are not FDA approved" and are not reviewed for safety, effectiveness or quality before sale (FDA, 2026).
- Dietary supplements. "By statute, the FDA does not approve dietary supplements for safety and effectiveness."
- Research-grade material. These are laboratory reagents for laboratory research use only, not for human or veterinary use, and they have no FDA label.
So a vial or pill sold online as "semaglutide" is not Ozempic or Wegovy. On who sets the dose, see semaglutide and tirzepatide dosage and where the dose of other peptide medicines comes from.
Which approved peptides are discontinued or no longer supplied?
Approval can outlast a product. Drugs@FDA lists these brands as discontinued: Zegalogue, Fuzeon, Iprivask, Natrecor, Vantas, Cubicin, Integrilin, Cancidas and Mycamine. Generic versions remain for several, including daptomycin, eptifibatide and caspofungin. For Cubicin, Drugs@FDA notes a Federal Register finding that it was not withdrawn for safety or effectiveness reasons (Drugs@FDA).
Two cases differ. Natpara's maker closed its U.S. special use program on December 31, 2025, with no shipments after that date (Takeda, 2025). For bacitracin, FDA asked in 2020 that approvals for the injectable form be withdrawn (Federal Register, 2022). Its first aid and eye products remain.
What does accelerated approval mean on this list?
Some approvals rest on an early measure of benefit and need later confirmation. The Voxzogo and Forzinity labels each state that the indication is approved under accelerated approval. Both add that continued approval may depend on confirmatory trials (Voxzogo label; Forzinity label). Wegovy's indication for MASH liver disease is also an accelerated approval (Wegovy label).
Which popular peptides are not FDA-approved?
Many peptides discussed online have no approval for any use. FDA says retatrutide has not been shown safe and effective for any condition. It "cannot be used in compounding under federal law" (FDA, 2026). BPC-157, TB-500, MOTS-c, KPV and others appear on FDA's list of compounding substances "previously in category 2," its significant-safety-risk group (FDA, 2026).
Our pages on retatrutide FDA approval, whether BPC-157 is legal and peptides and the FDA in 2026 explain where each stands. The legitimate routes to an unapproved drug are covered in how to find a peptide clinical trial.
How can you check a product's approval yourself?
- Search Drugs@FDA by brand or ingredient. Each approved application shows its approval history and marketing status (Drugs@FDA).
- Read the label on DailyMed, the National Library of Medicine's label database. It lists the approved uses and warnings.
- Buy only through a licensed pharmacy. FDA's BeSafeRx pages list the signs of a safe online pharmacy, starting with one that "always requires a doctor's prescription."
- Report problems to FDA through MedWatch, or call 1-888-INFO-FDA (1-888-463-6332) and press 2.
For the legal ways to get any of these medicines, see how to get peptides legally.
Frequently asked questions about FDA-approved peptides
Which peptides are FDA-approved?
Dozens, including semaglutide, tirzepatide, insulin analogs, oxytocin, octreotide, leuprolide, teriparatide and tesamorelin. Table 1 lists the 70 approved medicines covered in our library, with brand, first approval year and labeled use.
Are peptides FDA-approved?
Some are and many are not. Approval belongs to specific products for specific uses, so compounded copies, supplements and research-grade material are not FDA-approved even when they share a name.
Which peptides are FDA-approved for weight loss?
Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide) are approved for long-term weight management in eligible patients. Imcivree (setmelanotide) is approved for certain rare forms of obesity. All require a prescription.
Is BPC-157 FDA-approved?
No. BPC-157 has no FDA approval for any use, and FDA lists it among compounding substances previously in its significant-safety-risk category.
Is retatrutide FDA-approved?
No. As of November 17, 2026, retatrutide is an investigational drug, and FDA states it cannot be used in compounding under federal law.
Are compounded peptides FDA-approved?
No. FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold.
What to know now
- Many approvals: 70 approved peptide and small protein medicines are covered in our library.
- Product-specific: approval covers one product and its labeled uses, not copies.
- Not approved: compounded drugs, supplements and research-grade material.
- Popular but unapproved: retatrutide, BPC-157, TB-500 and MOTS-c.
- Check it yourself: Drugs@FDA for approval, DailyMed for the label.
What we're watching
New peptide approvals. A possible FDA filing for retatrutide. Confirmatory results for the accelerated approvals on this list.